vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and System1, Inc. (SST). Click either name above to swap in a different company.

System1, Inc. is the larger business by last-quarter revenue ($51.9M vs $37.2M, roughly 1.4× GYRE THERAPEUTICS, INC.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -26.0%, a 22.3% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -31.3%). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -21.8%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

System1 is an American Internet advertising company. Formerly known as OpenMail, it was founded in 2013. It describes itself as operating a "Responsive Acquisition Marketing Platform", and cites privacy as one of its principal foci, although it has been criticized for its influence on privacy-focused properties, including search engine Startpage.com. It is headquartered in Marina del Rey, California.

GYRE vs SST — Head-to-Head

Bigger by revenue
SST
SST
1.4× larger
SST
$51.9M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+64.7% gap
GYRE
33.4%
-31.3%
SST
Higher net margin
GYRE
GYRE
22.3% more per $
GYRE
-3.7%
-26.0%
SST
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
-21.8%
SST

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
SST
SST
Revenue
$37.2M
$51.9M
Net Profit
$-1.4M
$-13.5M
Gross Margin
95.3%
41.0%
Operating Margin
0.3%
-33.6%
Net Margin
-3.7%
-26.0%
Revenue YoY
33.4%
-31.3%
Net Profit YoY
-340.1%
4.8%
EPS (diluted)
$-0.01
$-3.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
SST
SST
Q4 25
$37.2M
$51.9M
Q3 25
$30.6M
$61.6M
Q2 25
$26.8M
$78.1M
Q1 25
$22.1M
$74.5M
Q4 24
$27.9M
$75.6M
Q3 24
$25.5M
$88.8M
Q2 24
$25.2M
$94.6M
Q1 24
$27.2M
$84.9M
Net Profit
GYRE
GYRE
SST
SST
Q4 25
$-1.4M
$-13.5M
Q3 25
$5.9M
$-18.5M
Q2 25
$1.6M
$-17.5M
Q1 25
$3.7M
$-15.9M
Q4 24
$569.0K
$-14.2M
Q3 24
$2.9M
$-23.6M
Q2 24
$4.5M
$-26.4M
Q1 24
$9.9M
$-10.5M
Gross Margin
GYRE
GYRE
SST
SST
Q4 25
95.3%
41.0%
Q3 25
94.7%
36.9%
Q2 25
95.7%
35.7%
Q1 25
95.9%
38.2%
Q4 24
95.8%
42.1%
Q3 24
96.2%
28.0%
Q2 24
96.9%
27.6%
Q1 24
96.4%
21.9%
Operating Margin
GYRE
GYRE
SST
SST
Q4 25
0.3%
-33.6%
Q3 25
22.7%
-25.3%
Q2 25
8.1%
-20.4%
Q1 25
10.3%
-17.6%
Q4 24
2.4%
-15.7%
Q3 24
16.6%
-24.6%
Q2 24
12.7%
-30.8%
Q1 24
29.7%
-30.4%
Net Margin
GYRE
GYRE
SST
SST
Q4 25
-3.7%
-26.0%
Q3 25
19.4%
-30.1%
Q2 25
5.9%
-22.4%
Q1 25
16.9%
-21.3%
Q4 24
2.0%
-18.7%
Q3 24
11.2%
-26.6%
Q2 24
18.0%
-27.9%
Q1 24
36.6%
-12.4%
EPS (diluted)
GYRE
GYRE
SST
SST
Q4 25
$-0.01
$-3.58
Q3 25
$0.03
$-2.30
Q2 25
$0.00
$-2.23
Q1 25
$0.00
$-0.21
Q4 24
$0.00
$-3.41
Q3 24
$0.01
$-3.37
Q2 24
$0.01
$-3.80
Q1 24
$0.03
$-0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
SST
SST
Cash + ST InvestmentsLiquidity on hand
$52.4M
$86.9M
Total DebtLower is stronger
$305.1M
Stockholders' EquityBook value
$106.0M
$30.5M
Total Assets
$166.1M
$405.0M
Debt / EquityLower = less leverage
10.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
SST
SST
Q4 25
$52.4M
$86.9M
Q3 25
$60.0M
$54.6M
Q2 25
$54.4M
$63.6M
Q1 25
$29.9M
$43.9M
Q4 24
$26.7M
$63.6M
Q3 24
$25.1M
$69.1M
Q2 24
$25.1M
$75.7M
Q1 24
$37.4M
$69.9M
Total Debt
GYRE
GYRE
SST
SST
Q4 25
$305.1M
Q3 25
$259.2M
Q2 25
$263.3M
Q1 25
$267.4M
Q4 24
$255.1M
Q3 24
$259.2M
Q2 24
$263.3M
Q1 24
$268.6M
Stockholders' Equity
GYRE
GYRE
SST
SST
Q4 25
$106.0M
$30.5M
Q3 25
$101.9M
$42.7M
Q2 25
$92.0M
$58.2M
Q1 25
$68.1M
$67.2M
Q4 24
$63.3M
$80.3M
Q3 24
$63.2M
$90.3M
Q2 24
$60.4M
$109.4M
Q1 24
$56.6M
$131.7M
Total Assets
GYRE
GYRE
SST
SST
Q4 25
$166.1M
$405.0M
Q3 25
$159.4M
$385.2M
Q2 25
$152.6M
$429.2M
Q1 25
$129.8M
$419.2M
Q4 24
$125.4M
$459.1M
Q3 24
$125.2M
$479.3M
Q2 24
$120.9M
$511.3M
Q1 24
$122.0M
$521.1M
Debt / Equity
GYRE
GYRE
SST
SST
Q4 25
10.01×
Q3 25
6.07×
Q2 25
4.53×
Q1 25
3.98×
Q4 24
3.18×
Q3 24
2.87×
Q2 24
2.41×
Q1 24
2.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
SST
SST
Operating Cash FlowLast quarter
$-5.6M
$-10.6M
Free Cash FlowOCF − Capex
$-5.8M
FCF MarginFCF / Revenue
-15.5%
Capex IntensityCapex / Revenue
0.4%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
SST
SST
Q4 25
$-5.6M
$-10.6M
Q3 25
$4.7M
$-2.1M
Q2 25
$2.1M
$24.5M
Q1 25
$-129.0K
$-15.9M
Q4 24
$-2.8M
$772.0K
Q3 24
$1.7M
$-5.0K
Q2 24
$-5.5M
$10.0M
Q1 24
$2.9M
$-16.0M
Free Cash Flow
GYRE
GYRE
SST
SST
Q4 25
$-5.8M
Q3 25
$4.0M
Q2 25
$1.8M
Q1 25
$-251.0K
$-16.0M
Q4 24
$-2.8M
Q3 24
$1.0M
$-36.0K
Q2 24
$-6.9M
Q1 24
$2.7M
FCF Margin
GYRE
GYRE
SST
SST
Q4 25
-15.5%
Q3 25
13.1%
Q2 25
6.8%
Q1 25
-1.1%
-21.5%
Q4 24
-10.1%
Q3 24
4.1%
-0.0%
Q2 24
-27.5%
Q1 24
9.8%
Capex Intensity
GYRE
GYRE
SST
SST
Q4 25
0.4%
0.0%
Q3 25
2.2%
0.0%
Q2 25
1.0%
0.0%
Q1 25
0.6%
0.1%
Q4 24
0.2%
0.0%
Q3 24
2.7%
0.0%
Q2 24
5.8%
0.0%
Q1 24
0.9%
0.0%
Cash Conversion
GYRE
GYRE
SST
SST
Q4 25
Q3 25
0.79×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons